Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month - Seite 2
Advocacy Events
As a dedicated partner to the LN community, Aurinia participates in events across the country throughout the year to promote awareness and uplift the people living with
LN. In May, Aurinia will attend the Lupus Research Alliance LuCIN Meeting in San Diego, CA, May 9-11; World Lupus Day, including the Lupus and Allied Diseases Association Tea Party, May 10; Aurinia
Legislative Townhall in Tampa, FL, May 18; and the Lupus Foundation of America Advocacy Day in Washington, D.C., May 19-21.
About Lupus Nephritis
Lupus Nephritis is a serious manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. About 200,000-300,000 people live with
SLE in the U.S., and about one-third of these people are diagnosed with lupus nephritis at the time of their SLE diagnosis. About 50 percent of all people with SLE may develop lupus nephritis. If
poorly controlled, lupus nephritis can lead to permanent and irreversible tissue damage within the kidney. Black and Asian people with SLE are four times more likely to develop lupus nephritis and
Hispanic people are approximately twice as likely to develop the disease, compared to White people with SLE. Black and Hispanic people with SLE also tend to develop lupus nephritis earlier and have
worse outcomes, compared to White people with SLE.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical
needs that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of
adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts
globally.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501574612/en/
The Aurinia Pharmaceuticals Stock at the time of publication of the news with a raise of +2,29 % to 4,775EUR on Tradegate stock exchange (30. April 2024, 22:26 Uhr).